EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSCHYG00000023094
Gene Symbol: GABRQ
1 Cross references
86 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSCHYG00000002285
Gene Symbol: GABBR1
1 Cross references
267 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSCHYG00000025615
Gene Symbol: GABBR2
1 Cross references
208 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSCHYG00000011385
Gene Symbol: GIPR
1 Cross references
93 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSCHYG00000018776
Gene Symbol: GLP1R
1 Cross references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSCHYG00000008962
Gene Symbol: GLP2R
1 Cross references
205 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSCHYG00000024352
Gene Symbol: GCGR
1 Cross references
184 Possible Orthologues:

Glucokinase

Ensembl ID : ENSCHYG00000019315
Gene Symbol: GCK
1 Cross references
216 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSCHYG00000005419
Gene Symbol: GBA1
1 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSCHYG00000011374
Gene Symbol: GRIA1
1 Cross references
325 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSCHYG00000000264
Gene Symbol: GRIA2
1 Cross references
322 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSCHYG00000015734
Gene Symbol: GRIA3
1 Cross references
249 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).